Transcription factor EB(TFEB),which belongs to the microphthalmia/transcription factor E(MiTF/TFE)family,is mainly functioned as regulator involved in regulating lysosomal function and autophagy.It plays an im-portant role in lipid metabolism via modulating lysosomal lipid degradation,mitochondrial β-oxidation of fatty acid,and in-tracellular cholesterol efflux.TFEB inhibits the development of metabolic associated fatty liver disease(MAFLD)and o-besity by regulating the autophagy and the expression of lipid metabolism-related genes.Additionally,it prevents the for-mation of foam cell from macrophages and vascular smooth muscle cells by restraining lipid accumulation,thereby attenua-ting the progression of atherosclerosis.TFEB promotes lipophagy to relieve lipid accumulation and lipid accumulation-in-duced insulin resistance,and β-cell failure,deferring diabetes-related lipid metabolic disorders.In summary,TFEB plays a key role in lipid metabolism and associated lipid disorder diseases,and serves as a potential clinical target to correct lipid dysmetabolism in vivo.

Transcription factor EB(TFEB),which belongs to the microphthalmia/transcription factor E(MiTF/TFE)family,is mainly functioned as regulator involved in regulating lysosomal function and autophagy.It plays an im-portant role in lipid metabolism via modulating lysosomal lipid degradation,mitochondrial β-oxidation of fatty acid,and in-tracellular cholesterol efflux.TFEB inhibits the development of metabolic associated fatty liver disease(MAFLD)and o-besity by regulating the autophagy and the expression of lipid metabolism-related genes.Additionally,it prevents the for-mation of foam cell from macrophages and vascular smooth muscle cells by restraining lipid accumulation,thereby attenua-ting the progression of atherosclerosis.TFEB promotes lipophagy to relieve lipid accumulation and lipid accumulation-in-duced insulin resistance,and β-cell failure,deferring diabetes-related lipid metabolic disorders.In summary,TFEB plays a key role in lipid metabolism and associated lipid disorder diseases,and serves as a potential clinical target to correct lipid dysmetabolism in vivo.